A detailed history of New Edge Advisors, LLC transactions in Incyte Corp stock. As of the latest transaction made, New Edge Advisors, LLC holds 6,972 shares of INCY stock, worth $491,804. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,972
Previous 23,087 69.8%
Holding current value
$491,804
Previous $1.4 Million 67.12%
% of portfolio
0.0%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$57.33 - $68.61 $923,872 - $1.11 Million
-16,115 Reduced 69.8%
6,972 $460,000
Q2 2024

Aug 15, 2024

BUY
$51.18 - $63.75 $228,058 - $284,070
4,456 Added 23.92%
23,087 $1.4 Million
Q1 2024

May 14, 2024

BUY
$56.55 - $66.59 $1.05 Million - $1.23 Million
18,532 Added 18719.19%
18,631 $1.06 Million
Q4 2023

Feb 13, 2024

BUY
$52.16 - $64.19 $5,163 - $6,354
99 New
99 $6,000
Q4 2022

Feb 14, 2023

BUY
$67.18 - $84.11 $561,154 - $702,570
8,353 New
8,353 $670,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.7B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.